New Patent Covering Enlivex’s AllocetraTM Immunotherapy Was Allowed By The Israeli Patent Authority
September 09 2019 - 7:30AM
Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company,
today announced that the Israeli Patent Authority issued a notice
of allowance for a patent application covering ALLOCETRATM, the
company’s immunotherapy product. Upon issuance, the new
patent will provide added intellectual property protection,
including methods, uses and pharmaceutical compositions. The
company expects that this new patent will be issued in Israel
during the second half of 2019.
ALLOCETRA™ is a novel immunotherapy based on a
unique mechanism of action that targets life threatening
diseases that are defined as “unmet medical needs” such
as preventing or treating complications associated with bone
marrow transplants (“BMT”) and/or hematopoietic stem cell
transplants (“HSCT); organ dysfunction and acute multiple organ
failure associated with sepsis and enablement of an effective
treatment of solid tumors via immune checkpoint
rebalancing. ABOUT ENLIVEX
Enlivex is a clinical stage immunotherapy
company, developing an allogeneic drug pipeline for immune system
rebalancing. Immune system rebalancing is critical for the
treatment of life-threatening immune and inflammatory conditions
which involve an out of control immune system (e.g. Cytokine
Release Syndrome) and for which there are no approved treatments
(unmet medical needs), as well as solid tumors immune-checkpoint
rebalancing. For more information, visitwww.enlivex.com.
Safe Harbor Statement: This
press release contains forward-looking statements, which may be
identified by words such as “expects,” “plans,” “projects,” “will,”
“may,” “anticipates,” “believes,” “should,” “would”, “intends,”
“estimates,” “suggests,” “has the potential to” and other words of
similar meaning, including statements regarding the results of
current clinical studies and preclinical experiments and the
effectiveness of ALLOCETRATM programs, which are made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect
Enlivex’s business and prospects, including the risks that Enlivex
may not succeed in generating any revenues or developing any
commercial products; that the products in development may fail, may
not achieve the expected results or effectiveness and/or may not
generate data that would support the approval or marketing of these
products for the indications being studied or for other
indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the
results of clinical and other trials in animals. The results of
early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products
using the ALLOCETRATM product line could also be affected by a
number of other factors, including unexpected safety, efficacy or
manufacturing issues, additional time requirements for data
analyses and decision making, the impact of pharmaceutical industry
regulation, the impact of competitive products and pricing and the
impact of patents and other proprietary rights held by competitors
and other third parties. In addition to the risk factors described
above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in
Enlivex’s filings with the Securities and Exchange Commission. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements,
except as required under applicable law.
ENLIVEX CONTACT: Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd. shachar@enlivexpharm.com
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024